Dendritic cells (DC) that have been genetically modified to express cytokine genes may be novel tools for inducing antitumor immune responses. In the present study, the pMX retroviral vector was modified to express the mouse IL-2 (mIL-2pMX) and mouse IL-12 (mIL-12pMX) genes. Supernatants from 293 cells transfected with pMX retroviral vectors were harvested and used to transduce mouse lin − bone marrow (BM) progenitor cells. After 48 h co-culture with pseudotype retrovirus, BM cells were cultured for 12 days in the presence of mGM-CSF, mSCF and mTNF-␣ to obtain a DC-enriched fraction. Flow cytometric analysis showed that GFP protein expression in these cultures was 20-40% and that 40-50% of the cultured BM cells were positive for the DC marker, DEC205. About 60% of cells sorted for DEC205 also expressed GFP. The supernatants of DC-mIL-2 and DC-mIL-12 cultured for 48 h contained 5.2 ± 0.15 and 33.9
Introduction
It is apparent that the induction of antitumor immune responses is complex and depends on successful antigen presentation. There are many factors that ultimately may contribute to suppression of tumor growth including the induction of apoptosis, engagement of cell-mediated cytotoxic mechanisms such as perforin or FAS-mediated killing and anti-angiogenic effects. Uptake and presentation of tumor antigens by antigen presenting cells (APC) is an important component for the engagement and development of adaptive antitumor immune responses. Dendritic cells (DC) are professional APC that can capture a broad range of tumor-derived antigens of variable molecular sizes, and after intracellular processing, present them in concert with major histocompatibility (MHC) molecules for stimulation of effector T cells. 1, 2 These antigen specific effector T cells may then mediate strong antitumor immunity, resulting in the eradication of tumor cells. ± 2.6 ng cytokine protein per milliliter, respectively. Intratumoral injection of DC-mIL-2 or DC-mIL-12 on days 8 and 15 after the intradermal injection of 1 × 10 5 B16F10 cells, resulted in a significant reduction in tumor size by day 21, as compared with mice treated with unmodified DC or DC-GFP. Longer term analysis as assessed at day 42 revealed that B16 tumor-bearing mice treated with cytokine genemodified DC survived significantly longer than mice from other groups. Spleen cells obtained from DC-treated mice were specifically sensitized for the generation of CTL by subsequent restimulation with gene-modified DC. These results suggested that DC genetically modified to express IL-2 or IL-12 can induce potent antitumor responses against wellestablished, poorly immunogenic B16F10 tumors. Gene Therapy (2000) 7, 2113-2121.
The functional aspects and physiology of DC in tumor sites are not yet fully understood. Some researchers have reported that DC detected in tumors are immature and their functions are inactivated by inhibitory cytokines such as IL-10 and vascular endothelial growth factor (VEGF). [9] [10] [11] Thus, the delivery of functional DC directly into tumor sites represents an alternative approach for potentiating a local endogenous antitumor immune response without actually pulsing DC with antigen in vitro. Such DC when injected intratumorally could capture tumor antigens that would be liberated locally by apoptosis/necrosis of some tumor cells during the interactions with host innate immune responses, migrate to regional lymph nodes, and help to initiate a systemic antitumor immune response. 12 In this study, we used DC transduced with the IL-2 or IL-12 genes for direct intratumoral injection. IL-12 is a 70-kDa heterodimeric molecule composed of linked p35 and p40 subunits. 13 IL-12 is mainly produced by macrophages, monocytes and DC, and has very diverse biological effects such as stimulating NK cells, enhancing CTL activities, inducing interferon (IFN)-␥ production by T and NK cells which contributes to Th1 immune responses and has been associated with anti-angiogenic effects. 14, 15 However, systemic delivery of both recombinant IL-2 and IL-12 proteins has been complicated by several dose-limiting side-effects. 16 We speculated that local delivery of these genes in the context of potent APC might serve as a trigger or amplifying mechanism to enhance antitumor immune responses. Our results show that the intratumoral injection of unmodified DC yields some therapeutic benefit, but that the expression of the IL-2 and in particular IL-12 genes enhances CTL activity and promotes an even greater antitumor response.
Results
Characterization of mIL-2 or mIL-12 gene-transduced murine DC developed from BM progenitor cells After the gene transduction procedure as described below (Figure 1 ), murine BM progenitor cells were cultured for 12 days in the presence of cytokines, and the total cell number per well in 24-well plates was determined for each group. The gene-transduction of BM progenitor cells had no significant effect on cell proliferation of any group (Figure 2 ). Surface marker analysis revealed most control DC to be DC marker (DEC205, CD11c) positive, and most were positive for class I/CD80 with a smaller number positive for class II/CD86. There was a tendency for the incidence of DEC205 expression to be higher in the GFP or cytokine gene-transduced groups, however this effect was not statistically significant (Table  1) . These results suggested that DC expressing a mature phenotype could be obtained from all six groups and that the gene transduction procedure did not significantly effect DC production from murine BM progenitor cells. In addition, mixed leukocyte reaction (MLR) assays showed that DC alone, DC-pMX(−) and DC-GFP could all induce potent allogeneic responses (data not shown).
Transduction efficiency of retroviral vectors
The transfection efficiency was evaluated using expression of GFP protein in DC-GFP on a flow cytometer (FACScan, Becton Dickinson, San Jose, CA, USA). The mean frequency of GFP expression was 31%, ranging from 20 to 40% in several similar experiments. In this study, the DC marker, DEC205 was expressed on 44% of the total cells (Figure 3 ). When DEC205 cells were positively sorted, approximately 60% of the sorted cells were GFP positive (data not shown). These results demon- strated that genes of interest were efficiently expressed in the majority of the cultured DC.
mIL-2 or mIL-12 p70 production from cytokine-gene transduced DC cultures The amounts of cytokines in supernatants conditioned by 2 × 10 5 gene-transduced DC for 48 h were measured. IL-2 and IL-12p70 levels in the supernatants were 5.3 and 34 ng per ml, respectively. IL-12p70 levels by DC alone or DC-GFP group were quite low, while the expression of the IL-2 gene in DC was also associated with a significantly higher (310 pg/ml) level of IL-12 production ( Table 2) .
Increased suppression of tumor growth in mice injected intratumorally with lL-2 or IL-12 gene-transduced DC When compared with the PBS control group, B16F10 tumor growth was significantly suppressed after day 15 in DC (P Ͻ 0.05), DC(−) (P Ͻ 0.05), DC-GFP (P Ͻ 0.05), DC-mIL-2 (P Ͻ 0.01) and DC-mIL-12 (P Ͻ 0.01) ( Figure  4 ). Mice injected with DC-mIL-2 or DC-mIL-12 showed more potent antitumor effects after day 18 than did the other groups (P Ͻ 0.05). The antitumor activity of the DC-mIL-12 group was significantly greater than that of DC-mIL-2 on day 18 and 20 (P Ͻ 0.05). Because some mice from each group were killed on day 21 for the CTL analyses described below, we performed a serial identical study to investigate a potential longer term survival benefit of cytokine gene-modified DC. The results shown in Table 3 demonstrated that most mice in the PBS(−), DC, DC(−) and DC-GFP groups were dead by day 42, while 11/12 mice treated with cytokine gene-modified DC continued to survive at this time. Overall, these results show that the intratumoral injection of control DC or DC transduced with GFP can also induce some antitumor effects, suggesting that the presence of mature DC in the tumor may have therapeutic benefits. However, the expression of either the IL-2 or IL-12 genes in DC results in more profound antitumor effects that can be documented by further increases in survival. was consistent with the antitumor activity of these groups shown in B16F10 tumor-bearing mice. CTL assays revealed that all groups showed more potent CTL activity against B16F10 tumor cells compared with the PBS control group (P Ͻ 0.01) at E/T ratios greater than 11. In addition, the DC-mIL-2 and DC-mIL-12 groups both exhibited higher CTL activity than any other groups at the E/T ratios greater than 11 (P Ͻ 0.05). Furthermore, CTL activity induced in mice injected with DC-mIL-12 was more potent than in mice injected with DC-mIL-2 at all E/T ratios tested (P Ͻ 0.05) ( Figure 5 ). CTL activity 
into mice. On day 7 and 14, PBS (-ș-), DC alone (-¼-), DC (−) (-˿-), DC-GFP (--), DC-mIL-2 (-᭝-) and DC-mIL-12 (-̆-) were injected intratumorally. Each point shows the mean ± s.d. of eight mice.
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from mice injected with DC or DC(−) was similar to that of DC-GFP (data not shown). No significant differences in NK activity were detected. Most importantly, CTL activity against 3LL lung cancer cells, another tumor syngeneic to C57BL/6 mice, was also not induced and no statistically significant differences in killing were detected among the groups. In addition, a blocking study using anti-CD8 or anti-class I (H-2K b /D b ) MoAb showed that anti-CD8 Ab inhibited CTL killing by 66% and 47%, and that anti-class I Ab inhibited by 39% and 44% in DCmIL-2 and DC-mIL-12 group, respectively ( Figure 6 ). This finding showed that significant CTL activity in the context of tumor antigen-class I restriction could contribute to the cytokine gene-modified DC-induced antitumor response. These results suggest that tumor-specific CTL activity may be a contributing factor in the antitumor effects of cytokine gene-modified DC against B16 tumors.
Serum IL-12p70 levels in tumor-bearing mice injected with cytokine gene-transduced DC In mice injected with DC-mIL-12, the IL-12p70 level in serum elevated gradually after the initiation of DC injection and reached 80 pg/ml by 7 days after the last injection. On the other hand, a low level of IL-12p70 was also detected in DC-mIL-2 injected mice on day 21 ( Figure 7 ).
Histological observations in B16F10 tumors from mice injected with IL-12-producing DC B16F10 tumors from mice injected intratumorally with IL-12-producing DC showed a remarkable disappearance of viable tumor cells and massive necrosis with a remarkably heavy infiltration of mononuclear and polymorphonuclear leukocytes. In contrast, no necrotic areas or associated cell infiltration could be seen in control mice injected with PBS ( Figure 8 ). In other groups including DC alone, DC(−) and DC-GFP groups, only small areas of necrosis and less markedly cell infiltration were observed.
Discussion
In recent years, there has been much excitement surrounding the potential therapeutic benefits of using DC in mice and humans. In particular, tumor-specific immunotherapy regimens using DC have been tested and some positive results obtained in several tumor types including melanoma, 17 B cell lymphoma, 18 colorectal cancers 19 or prostate cancers. However, in most cases, it has been obvious that advanced and/or poorly immunogenic tumors are refractory to immunotherapy possibly because of immunosuppressive effects in cancer patients, limited identification of cancer-specific antigens and possibly some tumor-regulated resistance mechanisms against immune effector cells such as expression of FAS ligand or down-regulation of tumor-specific MHC antigens. 20, 21 It is well accepted that DC are potent professional APC with the capability of inducing tumor-specific CTL activity and strong antitumor effects. In addition, it has been shown that DC pulsed with tumor-derived antigens including whole cell lysates, RNA and apoptotic bodies can trigger tumor-specific responses. [22] [23] [24] [25] This approach can be limited by the lack of defined tumor antigens for many cancers or the limitation in the amounts of clinical samples available for lysate preparation. Therefore, alter- 
at 37°C. These cells were washed, and then co-incubated with target or effector cells not treated with antibodies at the E:T ratio of 33:1 for 4 h. This blocking study revealed that anti-CD8 Ab inhibited CTL killing by 66% and 47% (a), and that anticlass I Ab inhibited by 39% and 44% in DC-mIL-2 and DC-mIL-12 groups (b), respectively. Data show the mean ± s.d. of triplicate samples. Open column: incubations with control antibodies; closed column: incubations with anti-CD8 or anti-class I MoAb.
native approaches for DC use that do not require exogenous tumor antigen may offer some practical benefits for initiation of adaptive immune responses.
In the present study, we used such an approach where DC that have not been pulsed with antigen were injected Gene Therapy
Figure 7 Serum IL-12 levels in B16F10 tumor-bearing mice injected with cytokine gene-transduced DC. On day 0, 7, 14 and 21, sera were obtained from three mice per group and mIL-12 p70 levels were measured by ELISA. Data represent the mean ± s.d. of three mice. PBS (-ș-), DC-GFP (--), DC-mIL-2 (-᭝-), DC-mIL-12 (-̆-).
directly into established tumors. Some benefit was derived from the use of unpulsed DC, but the effectiveness of this approach for treating established B16F10 tumors was enhanced when the DC had been transduced with the mIL-12 gene.
Very recently, Nishioka et al 26 reported that intratumoral injection of mIL-12 gene-transduced BM-DC showed potent antitumor effects in some murine syngeneic tumor models. Our results extend this observation by showing that lin − BM progenitor cells could be used instead of lymphocyte-depleted BM cells. The use of BM progenitor cells offers an alternative method for the introduction of cytokine genes prior to the expansion of DC containing populations. Several practically important points were derived from our experimental results. Specifically, the advantages of using BM progenitor cells for DC generation include (1) their early rapid growth phase in the culture which is suitable for retrovirus transfection; (2) the fact that progenitor-derived DC sometimes may show more potent antigen uptake (phagocytotic) ability; and (3) fewer DC may be required for the delivery via the intratumoral route for induction of potent antitumor effects and CTL-mediated killing. These observations indicated that using BM progenitor cells as the source of DC might be advantageous to immunotherapeutic approaches using cytokine gene-transduced DC.
In the present in vivo study, we also noted that B16 tumor-bearing mice injected intratumorally with geneunmodified or GFP gene-transduced DC showed a more potent antitumor effect when compared with the PBS(−) group. The effectiveness of unmodified DC is likely due to the ability of these unique cells to efficiently capture and process tumor antigens, migrate to regional lymph nodes and present the appropriate peptide to T cells. Ingulli et al 27 demonstrated that ex vivo OVA peptide pulsed-DC could migrate to lymph nodes after injection and stimulate the proliferation of OVA-specific T cells in an in vivo model. However, the biological events relating to antigen uptake by unmodified DC in the microenvironment of the lymph nodes still remain to be clarified. Some studies have been done to clarify the interaction of DC with tumor cells. Specifically, Nishioka et al 26 reported that intratumorally injected, unmodified DC were detected in the draining lymph nodes 24 h after injection. This result suggested that injected DC were viable and could migrate to the draining lymph nodes. Furthermore, with regard to the interaction between DC and tumor cells, it has been reported that DC tend to phagocytose apoptotic cells via ␣v␤5 integrin receptors, and DC can express the CCR7, mature chemokine receptor when they contact apoptosed tumor cells. 28 These results suggested that cell to cell contact between DC and tumor cells is the first important event required to trigger uptake of tumor antigens and subsequent migration by DC that then activate tumor-specific CTL.
In the present study, we have shown that some CTL activity was induced in B16F10-bearing mice after injection of unmodified or cytokine gene-transduced DC. Interestingly, NK activity against YAC-1 cells did not differ between groups. We have also done a blocking study using anti-CD8 or anti-class I (H-2K b /D b ) monoclonal antibody to clarify whether DC-mIL-2 or DC-mIL-12-induced CTL killing is B16 tumor-specific. The blocking study revealed that anti-CD8 Ab inhibited CTL killing by 66% and 47%, and that anti-class I Ab inhibited by 39% and 44% in DC-mIL-2 and DC-mIL-12 group, respectively. More importantly, CTL activity against 3LL lung cancer cells which are syngeneic to C57BL/6 mice was not efficiently induced by any treatment. These results suggest that tumor-specific CTL activity, not NK cells may be a major contributing factor for antitumor effects induced by cytokine gene-modified DC against B16 tumor.
The biological mechanism engaged in the enhanced effects induced by IL-12 gene-modified DC may be complex. It is possible that several discrete components could contribute to this process including NK and NKT cell activation, anti-angiogenic effects, CTL activation, secondary production of IFN-␥ and FAS up-regulation on tumor cells. [29] [30] [31] The unique benefits of IL-12 in this setting are also illustrated by our finding that secondary production of IL-12 from IL-2 gene-modified DC might be partially involved in the inhibition of tumor growth by these DC populations. The efficacy of IL-12 is further supported by other studies where naked DNA plasmids or viral vectors expressing IL-12 have been injected directly into the tumor site. 32, 33 However, it remains to be seen in direct comparison studies whether antitumor effects induced in this manner are qualitatively and quantitatively equivalent to effects induced by DC therapy.
In addition, there have been many reports using viral vectors to introduce cytokine genes into human DC derived from peripheral blood mononuclear cells (PBMC) or CD34
+ progenitor cells. [34] [35] [36] However, the transduction efficiency for introducing cytokine genes into human DC has been less effective than for mouse DC. Our results suggested that it may be appropriate to test this type of approach using human DC.
Overall, in the present study we have demonstrated that intratumoral injection of cytokine gene-modified DC showed remarkable antitumor effects and induced a systemic antitumor response in the absence of obvious sideeffects. These results suggest that this alternative approach for obtaining and using cytokine gene-modified DC may have value for the induction of antitumor responses in cancer patients.
Materials and methods
Production of retrovirus
The pMX retroviral vector was obtained from Dr Kitamura (Institute of Medical Science, Tokyo, Japan). 37 pCMHgag-pol, which encodes gag-pol gene was provided by Dr Kyoji Horie (National Cancer Institute, MD, USA) and pHCMV-G, an expression vector for vesicular stomatitis virus G (VSV-G) glycoprotein, was a gift from Dr Theodore Friedman, University of California, San Diego School of Medicine, CA, USA. The green fluorescent protein (GFP) gene was obtained from pGreen Lantern-1, purchased from Life Technologies (Gaithersburg, MD, USA). cDNAs for mIL-2, p35 and p40 of mIL-12 were amplified by RT-PCR from spleen cDNA from normal mice. The GFP, mIL-2 and mIL-12 fusion gene containing both the p40 and p35 gene sequence were subcloned into pMX and referred to as GFP-pMX, mIL-2-pMX and mIL-12-pMX, respectively. The pMX with no gene insertion was referred to as pMX(−).
In mIL-12-pMX, the termination codon of the p40 sequence and the signal sequence for p35 were eliminated, and these two subunits were linked by three repeats of amino acids, GlyGlyGlyGlySer (Figure 1 ). To generate pseudotype retrovirus, 293 cells in 60-mm dishes were transiently transfected simultaneously with three plasmids, one of the pMX retrovirus vectors, pCMHgag-pol (for gag-pol) and pHCMV-G (for VSV-G), using the calcium phosphate method. Forty-eight hours after the transfection, these supernatants were harvested, passed through 0.2-m filters and stored at −80°C until used for infection of DC. Transfection efficiency was more than 90% in 293 cells as determined by expression of GFP by fluorescent microscopy and the retroviral titer of the supernatants in the present experiments was at least 1 × 10 6 CFU/ml.
Cytokines and antibodies
Recombinant murine GM-CSF, mouse SCF, mouse TNF-␣ were purchased from Pepro Tech Inc (Rocky Hill, NJ, USA). These cytokines were used at the predetermined optimal concentrations as follows: GM-CSF 50 ng/ml, SCF 50 ng/ml, TNF-␣ 10 ng/ml. PE-labeled rat monoclonal antibody (MoAb) against murine dendritic cell antigen, DEC205, was kindly supplied by Dr K Komschlies (SAIC, Frederick, MD, USA). 
Mice and cell lines
Specific pathogen-free 6-8-week-old C57BL/6 mice were purchased from Charles River Japan (Atsugi, Kanagawa, Japan). The B16F10 murine melanoma cell line was kindly provided by Dr IJ Fidler (MD Anderson Cancer Center, Houston, TX, USA). The 3LL murine lung cancer cell line was provided by Dr RH Wiltrout (NCI-FCRDC, Frederick, MD, USA). The YAC-1 murine lymphoma cell line was purchased from ATCC (Manassas, VA, USA).
Culture of bone marrow progenitor cells and retroviral transduction of mIL-2 and mIL-12 genes Murine bone marrow (BM) cells were obtained and erythrocytes were lysed with ACK lysing buffer (Biowhittaker, Walkersville, MD, USA). Unfractioned BM cells were suspended in PBS + 2% FBS (GibcoBRL, Life Technology, Rockville, MD, USA) + 2 mm EDTA and exposed to a cocktail of MoAbs at the predetermined optimal concentrations: CD3, CD4, CD8, B220, Gr-1, CD11b, DX-5 and TER119. Sheep anti-rat IgG-conjugated immunomagnetic beads (Dynal, Oslo, Norway) were added and bead-bound cells were removed by a magnetic particle concentrator (Dynal). A population of lineage-negative (Lin − ) cells was obtained and resuspended in RPMI 1640 medium supplemented with l-glutamine (2 mm), penicillin (100 U/ml), streptomycin (100 U/ml) and 5% FBS, and incubated overnight with mGM-CSF, mSCF and mTNF-␣. ELISA specific for murine IL-2 and IL-12 p70 BM-derived DC were harvested 12 days after cytokine gene-transduction, and the amount of mIL-2 and IL12p70 released in supernatant were measured using murine IL-2 and IL-12 p70-specific ELISA kits (R and D Systems, Minneapolis, MN, USA). Cytokine levels were expressed as picograms/ml/48 h. In addition, blood was also collected from mice injected with genetically modified DC to measure IL-12 p70 levels in the serum. Detection limit of mIL-2 and mIL-12 p70 were 15.6 and 7.8 pg/ml, respectively.
Animal experiments
The various cohorts consisted of mice injected with PBS(−), DC, DC-pMX(−) (referred to below as DC(−)), DC-GFP-pMX, DC-mIL-2-pMX, DC-mIL-12-pMX. On day 0, all mice were injected i.d. in the right flank with 1 × 10 5 B16F10 cells. On days 7 and 14, eight mice per group were injected intratumorally with 3 × 10 5 nontransduced or transduced BM-derived DC. The mean tumor volume for all groups on day 7 was approximately 10-15 mm 3 . Mean tumor volume was calculated as follows: (width) 2 × (length) × 1/2. Longer-term survival was evaluated at day 42, and mean survival times for each group was determined and analyzed statistically.
Histological examination
Tumors from mice injected intratumorally with PBS(−), DC-mIL-2-pMX or DC-mIL-12-pMX were resected and fixed in 10% formalin solution, embedded with paraffin and stained with hematoxylin-eosin.
CTL assays
Spleens were harvested from two mice per group on day 21, 7 days after the last intratumoral DC injection. Spleens were dissociated and washed with PBS(−) containing 1% BSA (Fraction V; SIGMA, St Louis, MO, USA). Erythrocytes were lysed with ACK lysing buffer. After the filtration through cell strainers (Falcon, Cockeysville, MD, USA), spleen cells were resuspended in RPMI-1640 medium containing 10% FCS. 2.5 × 10 6 /ml of spleen cells were co-cultured with 2.5 × 10 5 /ml of irradiated (180 Gy) B16F10 cells in six-well culture plates in the presence of 2.5 ng/ml rmIL-2 for 5 days. Restimulated spleen cells were used as effectors for 51 Cr release assay. B16F10, YAC-1 or 3LL target cells were labeled with 100 Ci of Na 2
51
CrO 4 for 1 h at 37°C in 5% CO 2 . The labeled cells were washed three times, and mixed with effector cells at various E/T ratios in 96-well flat bottomed culture plates for 4 h. Blocking experiments for CTL activity against B16F10 cells were performed by incubating antimouse CD8 at a dose of 20 g/ml or anti-mouse H-2K b /D b MoAb at a 10 g/ml with effector or target cells respectively for 1 h at 37°C before a 4-h co-incubation. The supernatant was aspirated by means of a supernatant collecting system (Skatron, Sterling, VA, USA), and the radioactivity was counted in a gamma counter (Aloka, Mitaka, Tokyo). Spontaneous release was determined from the supernatants of the samples without effector cells. Maximal release was determined from the supernatants of the samples exposed to 0.1% triton. The percentage of specific lysis was determined by the following formula: percentage of specific lysis = (experimental release − spontaneous release)/(maximal release − spontaneous release) × 100.
Statistical analysis
Statistical differences were analyzed by unpaired twotailed Student's t test. Survival analysis of in vivo studies was performed by comparing differences in mean survival times via the Kaplan-Meier method. Comparative analysis of survival times between groups was then done using the logrank test. Values of P Ͻ 0.05 were considered statistically significant.
